Predictability of phenotype in relation to common β-lactam resistance mechanisms in Escherichia coli and Klebsiella pneumoniae

Journal of Clinical Microbiology

Volumn 54, Issue 5, 2016, Pages 1243-1250

  Agyekum, Alex ^a   Fajardo Lubián, Alicia ^a   Ai, Xiaoman ^a,d   Ginn, Andrew N ^a   Zong, Zhiyong ^a,e   Guo, Xuejun ^a,f   Turnidge, John ^b,c   Partridge, Sally R ^a   Iredell, Jonathan R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d BEIJING HOSPITAL   (China)

^e SICHUAN UNIVERSITY   (China)

^f BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; BETA LACTAMASE TEM 1; CARBAPENEMASE; CEFOTAXIME; CEFTAZIDIME; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; PORIN; PROTEIN OMPK36; TICARCILLIN; UNCLASSIFIED DRUG; BETA LACTAM; BETA LACTAMASE; OUTER MEMBRANE PROTEIN;

AMPC GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIAL GENE; BACTERIUM ISOLATE; BLATEM GENE; CONTROLLED STUDY; ESBL GENE; ESCHERICHIA COLI; GENE IDENTIFICATION; GENOTYPE PHENOTYPE CORRELATION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI INFECTION; GENETICS; GENOTYPE; HUMAN; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SECRETION (PROCESS);

AUSTRALIA; BACTERIAL OUTER MEMBRANE PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENOTYPE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE;

EID: 84964924293     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02153-15     Document Type: Article

References (69)

1. Pfeifer Y, Cullik A, Witte W. 2010. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 300:371-379. http://dx.doi.org/10.1016/j.ijmm.2010.04.005.
2. Cantón R, Coque TM. 2006. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 9:466-475. http://dx.doi.org/10.1016/j.mib.2006.08.011.
3. Jacoby GA. 2009. AmpC β-lactamases. Clin Microbiol Rev 22:161-182. http://dx.doi.org/10.1128/CMR.00036-08.
4. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 17:1791-1798. http://dx .doi.org/10.3201/eid1710.110655.
5. Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 18:263-272.
6. Queenan AM, Bush K. 2007. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440-458. http://dx.doi.org/10.1128 /CMR.00001-07.
7. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 41:563-569.
8. Crowley B, Benedi VJ, Doménech-Sánchez A. 2002. Expression of SHV-2 β-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob Agents Chemother 46:3679-3682. http://dx .doi.org/10.1128/AAC.46.11.3679-3682.2002.
9. Padilla E, Alonso D, Doménech-Sánchez A, Gomez C, Pérez JL, Albertí S, Borrell N. 2006. Effect of porins and plasmid-mediated AmpC β-lactamases on the efficacy of β-lactams in rat pneumonia caused by Klebsiella pneumoniae. Antimicrob Agents Chemother 50:2258-2260. http://dx.doi .org/10.1128/AAC.01513-05.
10. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:391-408. http://dx.doi.org/10 .1128/CMR.00047-06.
11. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http: //dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
12. Canica MM, Lu CY, Krishnamoorthy R, Paul GC. 1997. Molecular diversity and evolution of blaTEM genes encoding β-lactamases resistant to clavulanic acid in clinical Escherichia coli. J Mol Evol 44:57-65. http://dx .doi.org/10.1007/PL00006121.
13. Pérez-Pérez FJ, Hanson ND. 2002. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40:2153-2162. http://dx.doi.org/10.1128/JCM.40.6.2153-2162.2002.
14. Ellem J, Partridge SR, Iredell JR. 2011. Efficient direct extendedspectrum β-lactamase detection by multiplex real-time PCR: accurate assignment of phenotype by use of a limited set of genetic markers. J Clin Microbiol 49:3074-3077. http://dx.doi.org/10.1128/JCM.02647-10.
15. Espedido BA, Partridge SR, Iredell JR. 2008. blaIMP-4 in different genetic contexts in Enterobacteriaceae isolates from Australia. Antimicrob Agents Chemother 52:2984-2987. http://dx.doi.org/10.1128/AAC.01634-07.
16. Ginn AN, Zong Z, Wiklendt AM, Thomas LC, Merlino J, Gottlieb T, van Hal S, Harkness J, Macleod C, Bell SM, Leroi MJ, Partridge SR, Iredell JR. 2013. Limited diversity in the gene pool allows prediction of third-generation cephalosporin and aminoglycoside resistance in Escherichia coli and Klebsiella pneumoniae. Int J Antimicrob Agents 42:19-26. http://dx.doi.org/10.1016/j.ijantimicag.2013.03.003.
17. Ginn AN, Wiklendt AM, Zong Z, Lin RT, Teo JW, Tambyah PA, Peterson LR, Kaul K, Partridge SR, Iredell JR. 2014. Prediction of major antibiotic resistance in Escherichia coli and Klebsiella pneumoniae in Singapore, USA and China using a limited set of gene targets. Int J Antimicrob Agents 43:563-565. http://dx.doi.org/10.1016/j.ijantimicag.2014.02.010.
18. Agyekum A, Fajardo-Lubian A, Ansong D, Partridge S, Agbenyega T, Iredell J. 2015. blaCTX-M-15 carried by IncF-type plasmids is the dominant ESBL gene in Escherichia coli and Klebsiella pneumoniae at a hospital in Ghana. Diagn Microbiol Infect, 84(4):328-333. http://dx.doi.org/10.1016 /j.diagmicrobio.2015.12.010.
19. Zong Z, Partridge SR, Thomas L, Iredell JR. 2008. Dominance of blaCTX-M within an Australian extended-spectrum β-lactamase gene pool. Antimicrob Agents Chemother 52:4198-4202. http://dx.doi.org/10.1128 /AAC.00107-08.
20. Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597-1606. http://dx .doi.org/10.1093/jac/dks121.
21. Nordmann P, Poirel L, Carrer A, Toleman MA, Walsh TR. 2011. How to detect NDM-1 producers. J Clin Microbiol 49:718-721. http://dx.doi .org/10.1128/JCM.01773-10.
22. Rasheed JK, Anderson GJ, Yigit H, Queenan AM, Doménech-Sánchez A, Swenson JM, Biddle JW, Ferraro MJ, Jacoby GA, Tenover FC. 2000. Characterization of the extended-spectrum β-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother 44:2382-2388. http://dx .doi.org/10.1128/AAC.44.9.2382-2388.2000.
23. Hu YY, Cai JC, Zhou HW, Zhang R, Chen GX. 2015. Rapid detection of porins by matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Front Microbiol 6:784. http://dx.doi.org/10.3389/fmicb .2015.00784.
24. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
25. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/. Accessed 28 July 2015.
26. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 63:219-228. http://dx.doi.org/10.1016/j.mimet.2005.03.018.
27. Villa L, García-Fernández A, Fortini D, Carattoli A. 2010. Replicon sequence typing of IncF plasmids carrying virulence and resistance determinants. J Antimicrob Chemother 65:2518-2529. http://dx.doi.org/10 .1093/jac/dkq347.
28. Johnson TJ, Bielak EM, Fortini D, Hansen LH, Hasman H, Debroy C, Nolan LK, Carattoli A. 2012. Expansion of the IncX plasmid family for improved identification and typing of novel plasmids in drugresistant Enterobacteriaceae. Plasmid 68:43-50. http://dx.doi.org/10 .1016/j.plasmid.2012.03.001.
29. Poirel L, Bonnin RA, Nordmann P. 2012. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob Agents Chemother 56:559-562. http://dx.doi.org/10.1128/AAC .05289-11.
30. Carattoli A, Seiffert SN, Schwendener S, Perreten V, Endimiani A. 2015. Differentiation of IncL and IncM plasmids associated with the spread of clinically relevant antimicrobial resistance. PLoS One 10:e0123063. http: //dx.doi.org/10.1371/journal.pone.0123063.
31. Carlone GM, Thomas ML, Rumschlag HS, Sottnek FO. 1986. Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species. J Clin Microbiol 24:330-332.
32. Johnson TJ, Wannemuehler YM, Johnson SJ, Logue CM, White DG, Doetkott C, Nolan LK. 2007. Plasmid replicon typing of commensal and pathogenic Escherichia coli isolates. Appl Environ Microbiol 73:1976-1983. http://dx.doi.org/10.1128/AEM.02171-06.
33. Hopkins KL, Liebana E, Villa L, Batchelor M, Threlfall EJ, Carattoli A. 2006. Replicon typing of plasmids carrying CTX-M or CMY β-lactamases circulating among Salmonella and Escherichia coli isolates. Antimicrob Agents Chemother 50:3203-3206. http://dx.doi.org/10.1128 /AAC.00149-06.
34. Karim A, Poirel L, Nagarajan S, Nordmann P. 2001. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 201:237-241. http://dx.doi.org/10.1111/j.1574-6968.2001.tb10762.x.
35. Poirel L, Gniadkowski M, Nordmann P. 2002. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J Antimicrob Chemother 50:1031-1034. http://dx.doi.org/10.1093/jac/dkf240.
36. Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, De Champs C, Sirot J. 2003. Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother 52:29-35. http://dx.doi.org/10.1093/jac/dkg256.
37. Lartigue MF, Poirel L, Poyart C, Reglier-Poupet H, Nordmann P. 2007. Ertapenem resistance of Escherichia coli. Emerg Infect Dis 13:315-317. http://dx.doi.org/10.3201/eid1302.060747.
38. Tsai YK, Fung CP, Lin JC, Chen JH, Chang FY, Chen TL, Siu LK. 2011. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother 55:1485-1493. http://dx.doi.org/10 .1128/AAC.01275-10.
39. Fernández L, Hancock RE. 2012. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 25:661-681. http://dx.doi.org/10.1128/CMR.00043-12.
40. Doumith M, Ellington MJ, Livermore DM, Woodford N. 2009. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. Clinical isolates from the UK. J Antimicrob Chemother 63:659-667. http://dx.doi.org/10.1093/jac/dkp029.
41. Jacoby GA, Mills DM, Chow N. 2004. Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:3203-3206. http://dx.doi.org/10.1128 /AAC.48.8.3203-3206.2004.
42. Martínez-Martínez L. 2008. Extended-spectrum β-lactamases and the permeability barrier. Clin Microbiol Infect 14(Suppl 1):S82-S89.
43. García-Fernández A, Villa L, Carta C, Venditti C, Giordano A, Venditti M, Mancini C, Carattoli A. 2012. Klebsiella pneumoniae ST258 producing KPC-3 identified in Italy carries novel plasmids and OmpK36/OmpK35 porin variants. Antimicrob Agents Chemother 56:2143-2145. http://dx .doi.org/10.1128/AAC.05308-11.
44. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, Farrell AN, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 57:5258-5265. http://dx.doi.org/10.1128/AAC.01069-13.
45. Landman D, Bratu S, Quale J. 2009. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol 58:1303-1308. http://dx.doi.org/10.1099/jmm.0.012575-0.
46. Partridge SR, Ginn AN, Wiklendt AM, Ellem J, Wong JS, Ingram P, Guy S, Garner S, Iredell JR. 2015. Emergence of blaKPC carbapenemase genes in Australia. Int J Antimicrob Agents 45:130-136. http://dx.doi.org /10.1016/j.ijantimicag.2014.10.006.
47. Novais A, Rodrigues C, Branquinho R, Antunes P, Grosso F, Boaventura L, Ribeiro G, Peixe L. 2012. Spread of an OmpK36-modified ST15 Klebsiella pneumoniae variant during an outbreak involving multiple carbapenem- resistant Enterobacteriaceae species and clones. Eur J Clin Microbiol Infect Dis 31:3057-3063. http://dx.doi.org/10.1007/s10096-012-1665-z.
48. Carattoli A. 2009. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 53:2227-2238. http://dx.doi.org/10 .1128/AAC.01707-08.
49. Carattoli A. 2013. Plasmids and the spread of resistance. Int J Med Microbiol 303:298-304. http://dx.doi.org/10.1016/j.ijmm.2013.02.001.
50. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
51. EUCAST. 2013. EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media /PDFs/EUCAST-files/Resistance-mechanisms/EUCAST-detection -of-resistance-mechanisms-v1.0-20131211.pdf.
52. Espedido BA, Thomas LC, Iredell JR. 2007. Metallo-β-lactamase or extended-spectrum β-lactamase: a wolf in sheep's clothing. J Clin Microbiol 45:2034-2036. http://dx.doi.org/10.1128/JCM.02538-06.
53. Dimou V, Dhanji H, Pike R, Livermore DM, Woodford N. 2012. Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. J Antimicrob Chemother 67:1660-1665. http://dx.doi .org/10.1093/jac/dks124.
54. Balm MN, Ngan G, Jureen R, Lin RT, Teo JW. 2013. OXA-181- producing Klebsiella pneumoniae establishing in Singapore. BMC Infect Dis 13:58. http://dx.doi.org/10.1186/1471-2334-13-58.
55. Chudácková E, Bergerová T, Fajfrlík K, Cervená D, Urbásková P, Empel J, Gniadkowski M, Hrabák J. 2010. Carbapenem-nonsusceptible strains of Klebsiella pneumoniae producing SHV-5 and/or DHA-1 β-lactamases in a Czech hospital. FEMS Microbiol Lett 309:62-70.
56. Wu JJ, Wang LR, Liu YF, Chen HM, Yan JJ. 2011. Prevalence and characteristics of ertapenem-resistant Klebsiella pneumoniae isolates in a Taiwanese university hospital. Microb Drug Resist 17:259-266. http://dx .doi.org/10.1089/mdr.2010.0115.
57. Nelson EC, Segal H, Elisha BG. 2003. Outer membrane protein alterations and blaTEM-1 variants: their role in β-lactam resistance in Klebsiella pneumoniae. J Antimicrob Chemother 52:899-903. http://dx.doi.org/10 .1093/jac/dkg486.
58. García-Fernández A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, Carattoli A. 2010. An ertapenem-resistant extended- spectrum-β-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Antimicrob Agents Chemother 54:4178-4184. http://dx.doi.org/10.1128/AAC.01301-09.
59. Shin SY, Bae IK, Kim J, Jeong SH, Yong D, Kim JM, Lee K. 2012. Resistance to carbapenems in sequence type 11 Klebsiella pneumoniae is related to DHA-1 and loss of OmpK35 and/or OmpK36. J Med Microbiol 61:239-245. http://dx.doi.org/10.1099/jmm.0.037036-0.
60. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth BN, Hong Nguyen M. 2013. Epidemiology and molecular characterization of bacteremia due to carbapenemresistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 13:2619-2633. http://dx.doi.org/10.1111/ajt.12424.
61. Bruch MD, Gierasch LM. 1990. Comparison of helix stability in wild-type and mutant LamB signal sequences. J Biol Chem 265:3851-3858.
62. Wei SQ, Stader J. 1994. Two distinct regions of the LamB signal sequence function in different steps in export. J Biol Chem 269:1648-1653.
63. De la Cruz MA, Calva E. 2010. The complexities of porin genetic regulation. J Mol Microbiol Biotechnol 18:24-36. http://dx.doi.org/10.1159 /000274309.
64. Chang LW, Buising KL, Jeremiah CJ, Cronin K, Poy Lorenzo YS, Howden BP, Kwong J, Cocks J, Blood A, Greenough J, Waters MJ. 2015. Managing a nosocomial outbreak of carbapenem-resistant Klebsiella pneumoniae: an early Australian hospital experience. Intern Med J 45: 1037-1043. http://dx.doi.org/10.1111/imj.12863.
65. Alberti S, Rodriquez-Quiñones F, Schirmer T, Rummel G, Tomás JM, Rosenbusch JP, Benedí VJ. 1995. A porin from Klebsiella pneumoniae: sequence homology, three-dimensional model, and complement binding. Infect Immun 63:903-910.
66. Livermore DM, Woodford N. 2006. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 14:413-420. http://dx.doi.org/10.1016/j.tim.2006.07.008.
67. Hernández-Allés S, Albertí S, Alvarez D, Doménech-Sánchez A, Martínez- Martínez L, Gil J, Tomás JM, Benedí VJ. 1999. Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 145:673-679. http://dx.doi.org/10.1099/13500872-145-3-673.
68. Hong JH, Clancy CJ, Cheng S, Shields RK, Chen L, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother 57:2147-2153. http://dx.doi.org/10.1128/AAC.02411-12.
69. Shields RK, Nguyen MH, Potoski BA, Press EG, Chen L, Kreiswirth BN, Clarke LG, Eschenauer GA, Clancy CJ. 2015. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. Antimicrob Agents Chemother 59:1797-1801. http://dx.doi.org/10.1128/AAC.03894-14.